Logo image of TLIS

TALIS BIOMEDICAL CORP (TLIS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:TLIS - US87424L2079 - Common Stock

4.38 USD
+0.22 (+5.29%)
Last: 8/30/2024, 8:26:04 PM
4.49 USD
+0.11 (+2.51%)
After Hours: 8/30/2024, 8:26:04 PM
Fundamental Rating

3

Overall TLIS gets a fundamental rating of 3 out of 10. We evaluated TLIS against 188 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for TLIS as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, TLIS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year TLIS has reported negative net income.
TLIS had a negative operating cash flow in the past year.
In the past 5 years TLIS reported 4 times negative net income.
TLIS had a negative operating cash flow in each of the past 5 years.
TLIS Yearly Net Income VS EBIT VS OCF VS FCFTLIS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 -50M -100M -150M

1.2 Ratios

TLIS's Return On Assets of -69.35% is on the low side compared to the rest of the industry. TLIS is outperformed by 77.78% of its industry peers.
The Return On Equity of TLIS (-100.93%) is worse than 67.20% of its industry peers.
Industry RankSector Rank
ROA -69.35%
ROE -100.93%
ROIC N/A
ROA(3y)-68.16%
ROA(5y)-29.58%
ROE(3y)-86.99%
ROE(5y)-37.77%
ROIC(3y)N/A
ROIC(5y)N/A
TLIS Yearly ROA, ROE, ROICTLIS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 100 -100 -200

1.3 Margins

With an excellent Gross Margin value of 97.27%, TLIS belongs to the best of the industry, outperforming 100.00% of the companies in the same industry.
The Profit Margin and Operating Margin are not available for TLIS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.27%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TLIS Yearly Profit, Operating, Gross MarginsTLIS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -1K -2K

More info and screens

7

2. Health

2.1 Basic Checks

TLIS does not have a ROIC to compare to the WACC, probably because it is not profitable.
TLIS has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, TLIS has more shares outstanding
TLIS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TLIS Yearly Shares OutstandingTLIS Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 500K 1M 1.5M
TLIS Yearly Total Debt VS Total AssetsTLIS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

TLIS has an Altman-Z score of -10.46. This is a bad value and indicates that TLIS is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -10.46, TLIS is doing worse than 82.01% of the companies in the same industry.
There is no outstanding debt for TLIS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -10.46
ROIC/WACCN/A
WACC8.69%
TLIS Yearly LT Debt VS Equity VS FCFTLIS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 100M -100M 200M

2.3 Liquidity

A Current Ratio of 7.51 indicates that TLIS has no problem at all paying its short term obligations.
The Current ratio of TLIS (7.51) is better than 84.66% of its industry peers.
A Quick Ratio of 7.51 indicates that TLIS has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 7.51, TLIS belongs to the top of the industry, outperforming 88.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.51
Quick Ratio 7.51
TLIS Yearly Current Assets VS Current LiabilitesTLIS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 42.72% over the past year.
TLIS shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -65.21%.
Measured over the past years, TLIS shows a decrease in Revenue. The Revenue has been decreasing by -2.24% on average per year.
EPS 1Y (TTM)42.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.28%
Revenue 1Y (TTM)-65.21%
Revenue growth 3Y-42%
Revenue growth 5Y-2.24%
Sales Q2Q%-93.25%

3.2 Future

TLIS is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 6.67% yearly.
The Revenue is expected to grow by 154.95% on average over the next years. This is a very strong growth
EPS Next Y27.62%
EPS Next 2Y6.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-100%
Revenue Next 2Y154.95%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
TLIS Yearly Revenue VS EstimatesTLIS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2025 2M 4M 6M 8M 10M
TLIS Yearly EPS VS EstimatesTLIS Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 -50 -100

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

TLIS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year TLIS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TLIS Price Earnings VS Forward Price EarningsTLIS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TLIS Per share dataTLIS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y6.67%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

TLIS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TALIS BIOMEDICAL CORP

NASDAQ:TLIS (8/30/2024, 8:26:04 PM)

After market: 4.49 +0.11 (+2.51%)

4.38

+0.22 (+5.29%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)08-07 2024-08-07/amc
Earnings (Next)11-12 2024-11-12/amc
Inst Owners21.86%
Inst Owner Change0%
Ins Owners18.29%
Ins Owner Change0%
Market Cap7.97M
Revenue(TTM)989.00K
Net Income(TTM)-57.21M
Analysts36.67
Price Target5.1 (16.44%)
Short Float %0.25%
Short Ratio0.17
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.06
P/FCF N/A
P/OCF N/A
P/B 0.14
P/tB 0.14
EV/EBITDA N/A
EPS(TTM)-31.43
EYN/A
EPS(NY)-28.34
Fwd EYN/A
FCF(TTM)-23.99
FCFYN/A
OCF(TTM)-23.74
OCFYN/A
SpS0.54
BVpS31.15
TBVpS31.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -69.35%
ROE -100.93%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.27%
FCFM N/A
ROA(3y)-68.16%
ROA(5y)-29.58%
ROE(3y)-86.99%
ROE(5y)-37.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 53.85%
Cap/Sales 46.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.51
Quick Ratio 7.51
Altman-Z -10.46
F-Score4
WACC8.69%
ROIC/WACCN/A
Cap/Depr(3y)87.68%
Cap/Depr(5y)283.5%
Cap/Sales(3y)30.44%
Cap/Sales(5y)36.17%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.72%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%28.28%
EPS Next Y27.62%
EPS Next 2Y6.67%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-65.21%
Revenue growth 3Y-42%
Revenue growth 5Y-2.24%
Sales Q2Q%-93.25%
Revenue Next Year-100%
Revenue Next 2Y154.95%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y46.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-5.61%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y77.65%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y77.58%
OCF growth 3YN/A
OCF growth 5YN/A

TALIS BIOMEDICAL CORP / TLIS FAQ

Can you provide the ChartMill fundamental rating for TALIS BIOMEDICAL CORP?

ChartMill assigns a fundamental rating of 3 / 10 to TLIS.


What is the valuation status for TLIS stock?

ChartMill assigns a valuation rating of 0 / 10 to TALIS BIOMEDICAL CORP (TLIS). This can be considered as Overvalued.


What is the profitability of TLIS stock?

TALIS BIOMEDICAL CORP (TLIS) has a profitability rating of 1 / 10.


What is the financial health of TALIS BIOMEDICAL CORP (TLIS) stock?

The financial health rating of TALIS BIOMEDICAL CORP (TLIS) is 7 / 10.


What is the earnings growth outlook for TALIS BIOMEDICAL CORP?

The Earnings per Share (EPS) of TALIS BIOMEDICAL CORP (TLIS) is expected to grow by 27.62% in the next year.